Introduzione e opportunita’ alla Innovative Health Initiative- IHI

Elisabetta Vaudano DVM, PhD
24.10.2023

innovative health initiative

WHAT IS IHI?

FROM IMI TO IHI

IHI PARTNERS

IHI IS EUROPE'S NEW PARTNERSHIP FOR HEALTH

IHI is a **collaboration** between the EU and the biopharmaceutical, biotechnology, digital health and medical technology sectors, as well as academics, patients, regulators and other healthcare professionals.

IHI will build on the extensive experience of **IMI's 14 years and almost 200 projects** to build an interdisciplinary, sustainable, patient-centric health research partnership to help transform patients' lives.

The industry members that make up the new partnership are:

- COCIR
- EFPIA
- EuropaBio
- MedTech Europe
- Vaccines Europe

The public member in the partnership is the European Union, represented by the European Commission

innovative health initiative



Source: Council Regulation - Single Basic Act

innovative health initiative

IHI JU Budget

IHI will work to reach its objectives with the following resources:

- up to EUR **1.2 billion** provided by the European Union (Horizon Europe Health Cluster),
- at least EUR **1.0 billion** provided by the member industry associations,
- up to EUR **200 million** from Contributing Partners.

innovative health initiative

IHI´s general objectives

- Turn health research and innovation into **real benefits for patients and society**
- Deliver safe, effective health innovations that **cover the entire spectrum of care** – from prevention to diagnosis and treatment – particularly in areas where there is an unmet public health need
- Make Europe’s health industries globally **competitive**.

innovative health initiative

IHI contributes to EU policies

IHI’s projects are expected to contribute to EU policies:

- Horizon Europe (of which IHI is a part)
- Europe's Beating Cancer Plan
- The new Industrial Strategy for Europe
- The Pharmaceutical Strategy for Europe
- The European Health Data Space

IHI contributes to the UN Sustainable Development Goal 3 on ensuring healthy lives and promoting well-being for all at all ages.

innovative health initiative

IHI Synergies

- IHI builds on lessons learned from the Innovative Medicines Initiative

- IHI is not meant to be a direct continuation of IMI. Rather, IHI will build on IMI´s results and ongoing initiatives within a new platform with a broader scope, more partners and a wider stakeholder base.

- IHI will seek synergies with other Horizon Europe activities, including other European partnerships, as well as other EU and national programmes.

innovative health initiative

L’Agenda Strategica per la Ricerca e Innovazione di IHI (SRIA)

innovative health initiative

Strategic Research & Innovation Agenda

Focus

- **Cross-sectoral approaches** to facilitate creation of new products and services to **prevent, intercept, diagnose, treat and manage diseases** and foster recovery more efficiently.

Goal

- Lay foundations for development **of safer and more effective health care products or solutions** that respond to **unmet public health needs** and that can be implemented into healthcare systems.

Research supported by IHI should remain at precompetitive level

https://www.ihi.europa.eu/about-ihi/research-and-innovation-agenda

What's in the SRIA?

For each **specific objective**, the SRIA explains in detail:

- the current challenges
- how IHI could address them
- suggests potential outputs for IHI projects
- describes the medium to long-term impacts

ihi.europa.eu/about-ihi/research-and-innovation-agenda

innovative health initiative

Specific objectives

a. **Improve our understanding of the factors that affect our health** and the development and treatment of certain **diseases**.

b. **Integrate fragmented health research and innovation efforts** by bringing together health industry sectors and other stakeholders. This will enable the development of tools, data, platforms, technologies and processes to facilitate the prevention, diagnosis, treatment and management of diseases, especially in **areas of unmet public health need**

innovative health initiative

Specific objectives

c. **Demonstrate the feasibility of integrated healthcare solutions** that draw on various technologies from different sectors and address the needs of the people who will use them, such as patients and healthcare professionals.

d. **Make better of opportunities to gather health data and use it** in research and care, all while respecting relevant privacy legislation.

e. **Develop ways of assessing the value of innovative, integrated health care solutions** to patients, carers, healthcare professionals and organisations, and other stakeholders.

innovative health initiative

How call topics are generated

Council Regulation (EU) 2021/2085

Strategic Research and Innovation Agenda (SRIA)

Ideas for call topics

SIP review

Annual Work Programme (AWP). Includes the annual scientific priorities & call topics

Consultation with advisory bodies (SIP & SRG)

AWP adopted by IHI Governing Board

innovative health initiative

2 types of calls for proposals

single-stage

- Broad topic, not specific to one single product/technology/solution
- Private Members apply simultaneously with Public Members in mixed consortia
- Due to its openness and competitive character, private members can receive funding
- Pharma companies will abstain from requesting funding
- Industry partners build consortia with public partners (like in HE regular calls)
- Proposed budgets must include at least 45% in-kind contribution (e.g., 10 mil total budget: at least 4.5 mil in-kind provided by members of founding associations)

2-stage

- Topics and budget are determined by Private Members
- Applicant consortia of beneficiaries requesting funding submit a short proposal at stage 1
- The successful applicant consortium joins with the pre-identified industry consortium the second stage
- Private Members are not eligible for funding
- In fact, no funding will be made available for any company with annual turnover > 500M
- No requirement for applicant consortia to provide in-kind contributions in a two stage process

innovative health initiative

How does IHI work? Two-stage procedure



innovative health initiative

How does IHI work? Single-stage procedure

Topic definition

Input from the wider research community (Third Parties Ideas)

- Industry partners
- Potential contributing partners
- Other stakeholders in the health community

Science & Innovation Panel (S&IP)

Topic texts are approved by the IHI Governing Board, as part of the Annual Work Plan

Advisory Groups Consultation

Science & Innovation Panel (S&IP)

States' Representative Group (SRG)

Single-Stage Submission of Full Proposal

Evaluation process

Full Consortium (Public & Private Partners)

- Academics
- Hospitals
- Regulators
- Patients' Organisations
- SMEs
- For-profit legal entities (SMEs and larger enterprises)

Granting phase

Signature of Grant Agreements

(between project coordinator and IHI JU)

Signature of Consortium Agreements

(between partners)

Project launch!

innovative health initiative

Eligibility rules: Participation

Horizon Europe

- Any legal entity or international organisation regardless of its place of establishment
- At least 3 independent legal entities established in a different
  - Member State or
  - Associated Country

NEW

→ **IMPORTANT!**
1 legal entity should be established in a Member State

- IHI specific eligibility criterion
  - NOT applicable: stage one of two-stage calls:

NEW

Costs related to contributions provided by participants shall amount to at least 45% of the total project cost.

→ IKOP, IKAA or FC

innovative health initiative

Eligibility rules: funding for two-stage Calls

Non-profit organisations

Academic institutions

For-profit legal entities

(SME and larger enterprises with an annual turnover of less than EUR 500 million)

Any legal entity established in a Member State, Associated Country or Low and Middle Income countries

See Horizon Europe programme guide

NOT eligible for funding:

- Pre-identified Industry Consortium
- Any legal entities which is:

(a) A for-profit legal entity with an annual turnover of EUR 500 million or more

(b) A for profit legal entity directly or indirectly controlling/or being controlled by for profit legal entities with an annual turnover of EUR 500 million or more.

innovative health initiative

Eligibility rules: funding for single-stage Calls

- ☑ **Non-profit organisations**
  - Academics
  - Regulators
  - For-profit legal entities (SME and larger enterprises)
  - Hospitals
  - NGOs
  - Patients' Organisations
  - Public bodies
  - research organisations
  - intergovernmental organisations
- ☑ **Any legal entity established in a Member State, Associated Country or Low and Middle Income Countries**

See Horizon Europe programme guide

innovative health initiative

Fai domanda per i nostri fondi di ricerca

innovative health initiative

Funding opportunity

innovative health initiative

Deadline

call 4 **08.11.2023**

call 5 **16.01.2024**

- Reducing the environmental impact of healthcare
- Cutting the use of animals in health research
- Patient-centric blood sample collection
- Inclusive clinical studies
- Theranostics solutions
- Stroke management
- Synthetic data generation

IHI call 5 (single stage call)

- Accelerating the implementation of new approach methodologies and other innovative non-animal approaches for the development, testing and production of health technologies
- Development and proof of principle of new clinical applications of theranostics solutions
- Improved prediction, detection, and treatment approaches for comprehensive stroke management
- Maximising the potential of synthetic data generation in healthcare applications

innovative health initiative

Call 5 - single stage – Timelines

Early June 2023	• Publication of draft topics
27 July 2023	• Launch of the Call
16 January 2024	• Call Submission Deadline - Full Proposals (FP)
January - February 2023	• Scientific evaluation – FP
End March 2024	• Evaluation Outcome letters to the applicants
End of June 2024	• Grant Agreement Preparation (GAP) and GA signature

innovative health initiative

Single Stage Call - min 45% Industry contribution

"Private members, their constituents or affiliated entities and contributing partners must contribute at least 45% of the action's eligible costs and costs for its additional activities"

(IKOP + FC + IKAA) ≥ 45% of action's (eligible costs + IKAA)

If threshold not reached collectively → (full) proposal **NOT evaluated**

innovative health initiative

IHI call 5 topic spotlight



Non-animal approaches for developing, testing & producing health technologies

What's the problem?
Animals are still used in medical research, yet this raises ethical concerns, and results generated in animals do not always reliably predict what will happen in humans.

What do we want you to do?
Develop non-animal approaches and generate evidence to support their use in situations where animal-based tests are used currently, so that they can be used in key decision-making processes.

innovative health initiative

Accelerating the implementation of New Approach Methodologies and other innovative non-animal approaches for the development, testing and production of health technologies

Expected outcomes

- Reduction of animals used in biomedical research (contribution to 3Rs)
- Implementation of validated NAMs & other non-animal approaches in the development & production of health technologies
- Access to high-quality data in digital scalable repositories, new recommendations & best practices on such approaches & their integration in industrial processes
- Generation of robust evidence for regulatory decision-making

Expected impacts

- Benefit faster from safe & effective health technologies using approaches that generate more human-relevant data & are more predictive than current ones
- Generation of innovative approaches that can reduce time & costs, not dependent on shortages /issue with animals
- Achievement of regulatory validation & uptake of NAMs and other non-animal approaches for the development, testing and production of health technologies
- Development of health policies/standards on use of such approaches

innovative health initiative

Accelerating the implementation of New Approach Methodologies and other innovative non-animal approaches for the development, testing and production of health technologies

Need for Public-Private cross-sectorial Partnership

Cross-sectorial collaboration a must

to accelerate the development and use of effective NAMs and other non-animal approaches in the testing, development, and production of health technologies

Exchange of data, expertise and knowledge

to generate evidence on applicability of these approaches in industrial context & to support regulatory decision making

The value of involving partners with relevant expertise

industry (pharmaceutical, medical devices, *in vitro* diagnostics, vaccines), academia, SMEs + involvement of patients, regulators & policy makers

Indicative budget

- Topic budget: EUR 30 000 000.
- Project recommended budget EUR 12 000 000 to EUR 15 000 000
- at least 45 % (recommended 50%) of the action's eligible costs (+ IKAA if applicable) contributions [(IKOP, FC, IKAA) from private members and / or contributing partners.
- Contributing partners may not contribute IKAA.

innovative health initiative

IHI call 5 topic spotlight

New clinical applications of theranostics solutions

What's the problem?
Theranostics pairs a diagnostic test with a therapy that binds to the same target. It has the potential to be used as a safe, personalised treatment for diseases including cancer & neurological disorders.

What do we want you to do?
Develop innovative theranostic solutions plus tools and training resources for better monitoring of patient care, and increase Europe's theranostic manufacturing & treatment capacities.

innovative health initiative

Development and proof of principle of new clinical applications of theranostics solutions

Expected Outcomes

- Patients benefit from increased treatment efficacy, reduction of time to treat, fewer side effects, and reduced duration of hospitalisation.
- Healthcare professionals benefit from education, training on theranostic treatment approaches, recommendations, and clinical guidelines on the most appropriate use of theranostic solutions.
- European healthcare systems benefit from a broader spectrum of theranostic treatments and improved cost-effectiveness and affordability of theranostic solutions
- Technology developers, healthcare professionals and patients benefit from increased information on the sensitivity, quantification, stratification and staging of diseases.

Expected Impacts

- Improved availability of effective treatments for patients based on multi-modal theranostic solutions.
- Stronger resilience and improved strategic autonomy of Europe’s health systems, for example, by implementing new manufacturing capabilities (in accordance with the EU SAMIRA action plan).
- Depending on the disease area of the application, contributing to the Europe's Beating Cancer Plan and the Horizon Europe Mission on Cancer.

innovative health initiative

Development and proof of principle of new clinical applications of theranostics solutions

Need for Public-Private cross-sectorial Partnership

Theranostic solutions require a highly multidisciplinary team of specialists for their clinical application and integration in a patient treatment workflow. Therefore, a cross-sectorial collaboration is necessary for clinical deployment of theranostic solutions between

- Academia
- Healthcare professionals
- Health industry sectors

Indicative budget

- Topic budget EUR 25 000 000.
- Project recommended budget EUR 10 000 000 to EUR 12 000 000
- at least 45 % (recommended 50%) of the action's eligible costs (+ IKAA if applicable) contributions [(IKOP, FC, IKAA) from private members and / or contributing partners.
- Contributing partners may not contribute IKAA.

innovative health initiative

IHI call 5 topic spotlight

Improved prediction, detection & treatment for stroke management

What's the problem?
Stroke is a major cause of death and disability. Effective treatments exist, but many patients report that their care is impaired by poor coordination between the many groups involved in their treatment.

What do we want you to do?
Improve the integration and flow of data along the entire care pathway, and develop innovative tools and approaches to ensure a better management of stroke including prevention, diagnosis and treatment.

innovative health initiative

Improved prediction, detection, and treatment approaches for comprehensive stroke management

Expected outcomes

- Better access to integrated patients' health data and efficient coordination among and within stages of care and clinical specialties.
- More effective organisation of stroke management and personalisation of care delivery.
- New innovative modelling-based tools, and a more patient-centred definition of clinical outcomes after stroke.

Expected impacts

- Accelerated access to the healthcare system and holistic management of stroke that will lead to better health outcomes.
- Integrated, advanced solutions for prevention, diagnosis, and treatment of stroke, that facilitate decision-making by the different healthcare professionals involved in the stroke care pathway.
- Better implementation and scale up of existing treatments, ensuring wide coverage of the right treatment options for patients at the right time.
- Contribution to the 'European Health Data Space' (EHDS).

innovative health initiative

Improved prediction, detection, and treatment approaches for comprehensive stroke management

Need for Public-Private cross-sectorial Partnership



Breaking silos in healthcare

Bring the necessary diverse expertise together

Combine different types of resources

Indicative budget

- Topic budget EUR 40 000 000.
- Project recommended budget EUR 10 000 000 to EUR 13 000 000
- at least 45 % (recommended 50%) of the action's eligible costs (+ IKAA if applicable) contributions [(IKOP, FC, IKAA) from private members and / or contributing partners.
- Contributing partners may not contribute IKAA.

innovative health initiative

IHI call 5 topic spotlight

Maximising the potential of synthetic health data generation

What's the problem?
Synthetic health data can help to avoid some issues that arise when doing research with genuine patient data. However, it's not always clear which methods of generating synthetic data are best for different situations, and some methods are still immature.

What do we want you to do?
Develop and validate reliable methods of generating synthetic health data for specific use cases.

innovative health initiative

Maximising the potential of synthetic data generation in healthcare applications

Expected outcomes

- Wider availability of interoperable, synthetic data facilitating research and the development of integrated products and services to benefit patients.
- Improved insight into real-life behaviour and challenges of patients with complex, chronic diseases and co-morbidities thanks to m-health and e-health technologies.
- Advanced analytics/artificial intelligence tools supporting health research and innovation

Expected impacts

- Better understanding of the applicability and suitability of different synthetic data generation methods in specific use cases.
- Better tools, including open access when relevant, to create and share pools of synthetic patient data for research.
- Academic and industrial researchers have access to relevant, high quality synthetic datasets.
- Wider range of performant AI-based and other data-driven tools to support diagnostics, personalised treatment decision-making and prediction of health outcomes.

innovative health initiative

Maximising the potential of synthetic data generation in healthcare applications

Need for Public-Private cross-sectorial Partnership

Development and validation of synthetic data generation methods and tools for data-driven applications requires multidisciplinary collaboration across private and public entities including:

- Public and private data owners
- Healthcare solution developers
- Synthetic data experts.
- patients, who will benefit from the solutions.
- healthcare professionals to give insights on their experience with the current technology utilisation and act as champions for the new developments,

Indicative budget

- Topic budget EUR 24 000 000.
- Project recommended budget EUR 10 000 000 to EUR 12 000 000
- at least 45 % (recommended 50%) of the action's eligible costs (+ IKAA if applicable) contributions [(IKOP, FC, IKAA) from private members and / or contributing partners.
- Contributing partners may not contribute IKAA.

innovative health initiative

Applying for IHI call 4 or 5?

innovative health initiative

Catch up on the IHI Call Days!

Watch info sessions on all topics plus our rules and procedures and proposal finances

Register today and identify, message and meet **potential partners** for your consortium

Matchmaking is available until the call deadlines!

Find out more: **ihi.europa.eu**

Min 45% Industry contribution

- Coordinator of (full) proposal must submit a Declaration* (Annex) to confirm that the required 45% contribution will be provided

* For single stage proposals and two-stage full proposals. For short proposals, commitment is in call text.

- 45% commitment should be maintained during project implementation

- 45% can be reached with only one or two contribution type (e.g only with IKOP)

- Need to be a private member or contributing partner to contribute to the 45%

E.g.: before Grant signature, IHI office will check if private members are indeed members and if contributing partners have been approved by the IHI GB.

innovative health initiative

Type of contributions from private members of IHI, their constituents and affiliates entities

The private members of IHI JU are the private industry associations COCIR, EFPIA (including Vaccines Europe), EuropaBio and MedTech Europe.

The constituent and affiliated entities of the private members can provide three types of contributions to consortia implementing IHI JU projects:

- in-kind contributions to operational activities (IKOP) consist of the eligible costs for implementing the action;
- in-kind contributions to additional activities (IKAA) consist of costs for implementing additional activities;
- financial contribution (FC) consists of cash contributions to project beneficiary(ies) (or directly to IHI JU) to support the eligible costs incurred by the project beneficiary(ies) concerned in implementing the IHI JU action.

innovative health initiative

IHI Contributing Partners

Any country, international organisation or legal entity that wants to contribute to the IHI objectives can apply to become an IHI contributing partner

What are the benefits of being an IHI contributing partner?

- **Leverage funding:** In total, the EU can match up to EUR 200 million from contributing partners. Becoming an IHI contributing partner is an excellent way to make your resources stretch further while sharing risks.

- **Influence research:** As an investor in a project, you will be able to influence it from the earliest stages.

- **Networking:** be part of the wider collaborative health innovation ecosystem that IHI is creating giving you unprecedented opportunities for connecting, learning and capacity building,

- **Benefits of scale:** IHI expects to launch ambitious, large-scale, cross-sector projects addressing major challenges in health research and engaging stakeholders across the ecosystem with increase likelihood of having a real impact.

innovative health initiative

https://www.ihi.europa.eu/shape-our-future-research/become-contributing-partner

Type of contributions from contributing partners

A 'contributing partner' invests their own resources (which can be researchers' time, laboratories, data) or cash in a specific IHI JU project or projects. Their contributions work in a similar way to contributions by private members.

But there are some limitations:

- Contributing partners can contribute IKOP and FC to a project, but not IKAA.
- ➢ IKAA can only be contributed by the constituent and affiliated entities of the private members.
- In addition, contributing partners cannot contribute FC directly to IHI JU.

https://www.ihi.europa.eu/shape-our-future-research/become-contributing-partner

innovative health initiative

Intellectual Property Rights in IHI projects

- Emphasis on Exploitation and Open Science:
  - HE MGA integrates Open Science dissemination model;
  - Affordable Access Provisions can, when provided for in the call conditions, introduce additional exploitation obligations for relevant IHI topics;
  - Unexploited project results can be matched with interested parties via the Horizon Results platform.
- Some notable Access Rights changes from IMI2 JU to IHI JU*
  - Access Rights are now consistent with Horizon Europe MGA;
  - No third party access rights after project end for research use of results.

* Project IPR specificities to be agreed amongst all parties and detailed in the project Consortium Agreement

innovative health initiative

Intellectual Property Rights in IHI projects

- Horizon Europe legal basis applies (no specific derogations for IHI)
- IHI IPR rules derived from:
  - Horizon Europe Model Grant Agreement (MGA) Article 16;
  - supplemented by specific rules identified in HE MGA Annex V and;
  - where relevant, the applicable call conditions.
- IHI maintains right to object to transfers of ownership of results or to grants of exclusive licences.
- Results Ownership List ('ROL') to be submitted at project end as part of final periodic report listing all results and ownership of them (including joint ownership structures).

innovative health initiative

Tips for a successful proposal

- **Form your consortium early**
  - Always think “public-private partnership“
  - Include partners bringing in-kind contributions (45% eligibility)

- Provide **all information requested** in call text & proposal template
- Allow the evaluation experts to **easily assess your proposal against the evaluation criteria**

- Consider & plan for the **potential regulatory impact** of results
- READ ALL MATERIALS!

innovative health initiative

44

Tips for a successful proposal

You'll need to build or join a consortium!

- Network with **your contacts & IHI Call days participants:**
- https://ihi-call-days.ihi.b2match.io/
- Use EU Funding & Tenders portal **partner search tool:**
  - https://europa.eu/!QU87Nx
- Get in touch with your **IHI national contact point**:
  - https://europa.eu/!D7jyMy
- Network on social media:
  - www.twitter.com/IHIEurope
  - be.linkedin.com/company/innovative-health-initiative

45

- Influenza la nostra ricerca futura

Shape our future research and get involved

- **Become an evaluator / independent observer**
  ec.europa.eu/info/funding-tenders/opportunities/portal/screen/work-as-an-expert
- **Propose new ideas**
  ihi.europa.eu/shape-our-future-research/propose-ideas
- **Contribute at programme level:**
  - join an industry association
  - become a Contributing Partner
    ihi.europa.eu/shape-our-future-research/become-contributing-partner
- **Apply to IHI Calls**

innovative health initiative

Become an evaluator/expert/independent observer

IHI appoints external independent experts to assist in the evaluation of grant applications and projects

If you have a high level of expertise in fields relevant to IHI register on the Horizon Europe Funding & Tender Opportunities portal ec.europa.eu/info/funding-tenders/opportunities/portal/screen/work-as-an-expert

and then, send us an email at infodesk@ihi.europa.eu expressing your interest

If you already have a profile, please make sure that it is up-to-date.

innovative health initiative

Send us your ideas for IHI projects

- Many ideas for call topics come from our partners (industry members and the European Commission) and from contributing partners, but **we also welcome ideas from the wider health and research community**.

- All ideas will have to demonstrate
  - how they would help IHI to achieve its goals;
  - how they are aligned with the IHI SRIA;
  - why they need a cross-sectoral public-private partnership.

- Ideas will be assessed by the IHI Programme Office and governance bodies.

- Use the submission platform on the IHI website: https://www.ihi.europa.eu/shape-our-future-research/propose-ideas.

innovative health initiative

Get involved at programme level

- **Join one of the industry trade associations** who are IHI founding members: COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe

- **Apply to become an IHI contributing partner** (similar to the status of IMI2 associated partner)

innovative health initiative

Data, new technologies and digitalisation

- Data, new technologies, digitalisation and cross-sectoral collaboration will be at the core of IHI projects
- Build upon experience (and assets) of IMI1 and IMI2
- IHI focus will be to go beyond medicines development and supports the translation of scientific progress, technology advances and big data opportunities to improve health care
  - Particular focus on the patient journey - prevention, diagnosis, treatment and management of diseases/conditions
- IHI office is a neutral platform that allows researchers, industries (large and small, different sectors), regulatory bodies, healthcare providers, healthcare professionals, patients, carers to work together
- Keep in the precompetitive space

innovative health initiative

Almost 10,000 publications to date

9,784

IMI publications



IMI-funded projects continue to produce a large number of publications, reaching 9.784 publications to date. In 2022 IMI projects generated 1,144 publications. In the past 5 years IMI publications have surpassed the bar of 1.000 publications registered each year.

innovative health initiative

https://www.ihi.europa.eu/sites/default/files/uploads/Documents/About/Reports/IHI_Bibliometrics_Report_2023_Final.pdf

IMI interactions with EMA

- EMA representative in IMI Scientific Committee
- EMA beneficiary in some IMI projects (e.g., ConcePTION, PREMIER, SISAQOL-IMI) and on the advisory boards of projects (e.g., Gravitate-Health, ARDAT, EU-Pearl)

- Many of our consortia have interacted with EMA mainly through:
  - Innovation Force Task, Briefing meeting
  - Qualification advice/opinion procedure of novel methodologies for medicine development
  - Presentation at working parties

- IMI-EMA-FDA Regulatory Science Summit

innovative health initiative

Regulatory body engagement under IHI

- Given the goals and objectives of IHI we expect more engagement between funded projects and regulatory bodies
- This engagement will cover a broader range of issues and challenges
- Big differences between the medicines and medical devices development process and life cycle
- Integrated solutions?

innovative health initiative

First IHI projects

Signature of **5 Grant Agreements** from the 1st Call (proposals selected for funding):

- **CLAIMS** - diagnostic platform for Multiple Sclerosis based on AI models
- **IMAGIO** - using imaging techniques to guide minaturised instruments to cancer sites for more precise treatments
- **PROMINENT** - digital platfrom to improve diagnosis and treatment of people with Alzheimer's disease
- **GUIDE.MRD** - developing better blood tests for the detection of cancer
- **IDERHA** - RWE to improve detection and outcomes in lung cancer

innovative health initiative

NEW! Pubblicazione testi preliminari dei primi bandi 2024

ihi.europa.eu

I seguenti topics sono in consultazione per inclusion nei bandi: IHI call 6 (two-stage) and IHI call 7 (single-stage):

IHI call 6 (two-stage)

- Support healthcare system resilience through a focus on persistency in the treatment of chronic diseases
- Development of practical guidance and recommendations for using real world data/real world evidence in healthcare decision-making

IHI call 7 (single-stage)

- Improving clinical management of heart disease from early detection to treatment
- User-centric technologies and optimised hospital workflows for a sustainable healthcare workforce
- Clinical validation of biomarkers for diagnosis, monitoring disease progression and treatment response

I TESTI DEI BANDI 2024 SONO ANCORA PRELIMINARI E POTREBBERO SUBIRE SIGNIFICANTI MODIFICAZIONI

La piattaforma di networking e' stata aggiornata **ed e' gia possibile cominciare il networking per formare I consorzi**: https://ihi-call-days.ihi.b2match.io/

https://www.ihi.europa.eu/apply-funding/future-opportunities

innovative health initiative

Fonti di informazione e contatti

- Sign up for our monthly newsletter: www.ihi.europa.eu/news-events/newsletter
- Follow us on Twitter (X) @IHI_Europe
- Follow us on LinkedIn: Innovative Health Initiative (IHI)
- Questions? E-mail us: infodesk@ihi.europa.eu

innovative health initiative

innovative health initiative

Grazie per la vostra attenzione!

ihi.europa.eu

COCIR Advancing Healthcare

efpia

EuropaBio The European Association for Bioindustries

MedTech Europe from diagnosis to cure

Vaccines Europe

Co-funded by the European Union